Kornimate/medical-research-clean huggingface dataset:
promotion of influenza vaccination in healthcare workers during the recruitment visit

Conditions: Human Influenza Vaccination in Healthcare Workers

Summary: the investigators will compare two groups, an intervention group with a control group. each employee of the university hospital of lausanne (chuv) and the university medical policlinic of lausanne (pmu) who will do his recruitment visit at the occupational medicine unit of the chuv between 04/29/16 (end of previous influenza epidemic) and 31/10/16 (the day before the start of the next influenza vaccination campaign) and exert a function in regular contact with patients will be eligible. depending on his employee number (assigned by the human resources administration, independent of any parameter), he will be placed in the intervention group g1 (odd number) or in the control group g2 (even number). the information concerning the distribution of these two groups will be noted in the computerized medical records of the employee at the occupational medicine unit (medipho4d software, secured database). thereafter, the employee will be received by the nurse of the he occupational medicine unit for a recruitment visit according to the usual process. the nurse will perform the study intervention in addition to the usual procedure if it is stipulated ''intervention group'' on the employee's record in the database or only perform the usual steps if it is stipulated ''control group''. at the beginning of the next influenza vaccination campaign (mid-november 2016), employees in the intervention group will receive a letter reminding then about the intervention given during the recruitment visit and inviting them to get vaccinated. during the next influenza vaccination campaign (11.01.16) and until the end of the influenza epidemic that will follow (april 2017), each employee will have the opportunity to be vaccinated at the different vaccination stalls set up by the occupational medicine unit. for each employee vaccinated, the date of vaccination and vaccine name is entered in the electronic medical records of the occupational medicine unit (medipho4d software) by a nurse or a secretary of the unit. at the end of the human influenza epidemic (april 2017), the data will be extracted from the database (medipho4d software) and anonymized by an individual not implicated in the study. data from two groups will be analyzed and compared to assess whether the intervention conducted among newly hired employees promotes influenza vaccination.


Eligibility criteria:
inclusion criteria: * ≥ 18 years old * employees of chuv (university hospital of lausanne) or pmu (university policlinic of lausanne) who work regularly in contact with patients * employees who must do the recruitment visit at the occupational medicine unit of the chuv exclusion criteria: * no exclusion criteria
the sentry study: testing whether changes in platelet rna enhance the early diagnosis of ovarian cancer

Conditions: Ovarian Cancer

Summary: the purpose of the sentry (stability enhanced transcriptional analytics) study is to test whether combining a unique analytical approach with changes in platelet rna expression accurately diagnoses ovarian cancer. using retrospective data, the investigators have developed an approach that appears to accurately classify ovarian cancer with relatively high sensitivity and specificity. the sentry study will build upon these retrospective analyses to prospectively recruit women with ovarian cancer or an ovarian mass (and healthy control women), obtain platelet rna samples from whole blood, and perform validation analyses to test our hypothesis.


Eligibility criteria:
study population 1: women with a recent diagnosis of ovarian cancer (n=90) inclusion criteria: 1. women aged 21 years or older 2. diagnosed with any stage or type of ovarian cancer within the last 8 weeks exclusion criteria: 1. any other active malignancy 2. other diagnosis of any cancer within the last 6 months 3. treatment for any cancer within the last 6 months 4. history of ovarian cancer at any time 5. currently receiving chemotherapy for ovarian cancer 6. has already undergone complete ovarian mass resection 7. unable to provide blood sample study population 2: control women without ovarian cancer (n=30) inclusion criteria: 1. women aged 21 years or older exclusion criteria: 1. any active malignancy or diagnosis of cancer within the last 6 months 2. treatment for any cancer within the last 6 months 3. hospitalization or surgery (other than minor surgery such as mole removal) within the last 8 weeks 4. renal failure (defined as egfr \< 60 ml/min/1.73m² or on dialysis) 5. liver failure (defined as having hepatic encephalopathy of any degree, or moderately severe coagulopathy defined as inr ≥ 1.5, or known cirrhosis, or alt of ≥ 10x uln, or total bilirubin of ≥ 3.0 mg/dl, or diagnosis of liver failure) 6. decompensated or end-stage heart failure (defined as acc/aha stage c or stage d heart failure) 7. poorly controlled diabetes mellitus (defined as a hba1c \> 9.0%) 8. venous thrombosis, myocardial infarction, or stroke within the last 8 weeks 9. currently pregnant or have been pregnant within the last 12 weeks 10. any blood product transfusion within the last 8 weeks 11. personal history of ovarian cancer at any time 12. history of bilateral salpingo-oophorectomy 13. history of oophorectomy 14. unable to provide blood sample study population 3: women with a recent diagnosis of ovarian mass (n=125) inclusion criteria: 1. women aged 21 years or older 2. diagnosed with any type of ovarian mass within the last 8 weeks exclusion criteria: 1. any diagnosis of active malignancy 2. any diagnosis of any cancer within the last 6 months 3. treatment for any cancer within the last 6 months 4. history of ovarian cancer at any time 5. currently receiving chemotherapy for ovarian cancer 6. has already undergone complete ovarian mass resection 7. unable to provide blood sample
dihydroartemisinin- piperaquine versus artemether- lumefantrine in the treatment uncomplicated plasmodium falciparum malaria in sudan

Conditions: Malaria

Summary: dihydroartemisinin- piperaquine is not inferior to artemether-lumefantrine


Eligibility criteria:
inclusion criteria: * uncomplicated malaria exclusion criteria: * severe cases * pregnancy

Keywords: antimalarials acts piperaquine uncomplicated
feasibility and acceptability of a substance use screening and brief intervention for youth living with hiv in kenya

Conditions: Substance Use; Substance Use Disorders

Summary: youth living with hiv in kenya frequently use substances and this negatively affects their mental health as well as viral suppression. the goal of this study is to evaluate the feasibility and acceptability of a peer-delivered substance use screening and brief intervention for these youth.

globally, youth are disproportionately affected by substance use. in sub-saharan africa (ssa), an estimated 41% of youth have used at least one substance in their lifetime. youth living with hiv (ylh) have not been spared. in a study conducted in kenya, 33% and 46% of youth attending a hiv clinic reported harmful patterns of alcohol and illicit substance use respectively. substance use among ylh has been associated with negative outcomes including antiretroviral therapy (art) non-adherence, neurocognitive deficits, poor virologic control and depression. unfortunately, ylh in ssa lack access to substance use interventions. a study conducted by parcesepe et al reported that only 37% of hiv adolescent sites in select lmics offered any substance use screening and interventions. the world health organization (who) recommends screening and brief intervention (sbi) in primary healthcare for identification and early intervention for substance use. primary healthcare workers in lmics are however often unable to implement sbi due to heavy workload. peers represent a potential means through which sbi may be delivered in adolescent hiv settings and presents a number of advantages. first, peer support systems are well established in many adolescent hiv clinics in sub-saharan africa. secondly, by drawing upon their shared experiences as youth living with hiv, the peers can provide empathic support to the adolescents. few studies have evaluated implementation of peer-delivered sbi for adolescents. available studies have been conducted in high-income countries. to our knowledge, no study has evaluated implementation of peer-delivered sbi among ylh. our project seeks to fill this gap by evaluating the feasibility and acceptability of a peer-delivered sbi for ylh in kenya. this project is in line with: (i) kenyan ministry of health guidelines for delivery of adolescent and youth friendly services which lists substance use counseling as an essential service, and (ii) united nations programme on hiv/aids (unaids) fast-track target 95-95-95, which requires that by 2030, 95% of people on art be virally suppressed (12) as well as target 3.5 of the sustainable development goals (sdgs) which requires that governments strengthen the treatment and prevention of substance abuse. data from this study will set the stage for full-efficacy trials and ultimately to scale-up efforts to other lmics.

Eligibility criteria:
inclusion criteria: • youth aged 15-24 years exclusion criteria * those ill during the appointment * those who decline to assent/consent * youth unable to speak fluently in english.
combination of atg-based conditioning regimen and ptcy for gvhd prevention in allo-hsct after pd-1 blockade

Conditions: Graft-versus-host Disease; Hematological Malignancies

Summary: the aim of this study is to evaluate the efficacy and safety of anti-thymocyte globulin combined with ptcy (post-hsct cyclophosphamide, ptcy) in preventing graft-versus-host disease (gvhd) in allo-hsct patients after anti-pd-1(anti-programmed cell death protein 1) antibody treatment. in this study, patients with hematological malignancies who needed to receive allo-hsct after pd-1 antibody treatment were selected as the research subjects. fludarabine and busulfan was used as the conditioning regimen, and the dose of atg (anti-thymocyte globulin, atg) combined with ptcy was used as the gvhd prevention regimen. the aim of this study is to reduce the incidence of regimen-related toxicity and gvhd without affecting engraftment and relapse, thereby reducing non-relapse mortality and further improving the survival of patients.

atg (anti-thymocyte globulin, rabbit; 5 mg/kg, day -5 to -2) was used in matched sibling donor-hsct. atg (1.5 mg/kg, day -5; 2.5 mg/kg, day -4; mathematical function was then exploited to determine the total targeted atg dose on day -3 to -2 based on concentrations of active atg on day -5 to -4) was used in both haploidentical donor-hsct and unrelated donor-hsct. reduced-dose ptcy regimen: two doses of 14.5 mg/kg cy were given on days +3 and +4 post-hsct.

Eligibility criteria:
inclusion criteria: * (1) age ≥ 18 years old, regardless of gender; * (2) patients with hematological malignancies (including lymphoma, leukemia, myelodysplastic syndrome, etc.) who had received at least one course of pd-1 antibody treatment; * (3) patients with indications for allo-hsct, available donors (including matched sibling donors, haploidentical donors and unrelated donors), and no contraindications for transplantation; * (4) patients suitable for conventional bu/flu conditioning regimen; * (5) no serious heart, liver, kidney, lung and other important organ diseases; * (6) eastern cooperative oncology group (ecog) performance status score 0-2; * (7) hematopoietic stem cell transplantation comorbidity index (hct-ci) score was 0-3; * (8) expected survival time of at least 12 weeks; * (9) women who are not pregnant or breastfeeding; * (10) voluntary participation in clinical research; they or their legal guardians were fully aware of the study and signed informed consent. willing to follow and complete all trial procedures; exclusion criteria: * (1) pregnant or lactating women; * (2) other serious conditions that may limit enrollment (e.g., advanced infection, etc.); * (3) unable to understand and follow the study protocol or sign the informed consent form.
breast cancer chemotherapy risk prediction mathematical model

Conditions: Breast Neoplasms

Summary: this is a cohort study. this study is to develop a predictive model of the side effects after chemotherapy, exploreing the potential risk factors of the side effects such as myelosuppression and chemotherapy realted vomit after the chemotherapy, so that it could help to alleviate patients' fear and anxiety about the side effects and the toxicity of chemotherapy. the potential risk factors were measured at baseline.

firstly, the investigator will extact the "macro" information about physical conditon, which comes from syndrome-constitutional differentiation in the light of traditonal chinease medicine (tcm) theory. then combined with the "micro" information about pathological and biological markers, "tcm clinical phenotype" is extracted by text mining, and shows the full picture of the clinical features of breast cancer, which will include most of risk factors related to occurrence of adverse of chemotherapy fo breast cancer patients to establish two corresponding quatitative databases. furthermore, predictive models will be built according to the predictors selected from an analysis on new methods of econometrics-granger causality and cointegration analysis between "tcm clinical phenotype" and adverse effects of chemotherapy. the research results will be used to establish effective predictive models to lay the foundation for optimizing individualized treatment program of breast cancer by tcm and western medicine.

Eligibility criteria:
inclusion criteria: * the female patients diagnosed with breast cancer by first histopathology; * no tumor intervention therapy was conducted within one prior to the survey; * kps score≥60; * patients without sever idiopathic disease; * patients who can independently respond to a questionnaire * those who signed informed consent exclusion criteria: * patients with sever idiopathic disease of the gastrointestinal tract, heart and blood vessels, liver,kidney, hematopoietic system, endocrine system and so on; * patients with previous or nogoing application of drugs affecting bone marrow hemoatopoietic function; * patients who complicated with a serious infection or severe liquid sickness; * psychiatric patients; * those who can not independently respond to a questionnaire
a longitudinal examination of unpaid caregivers of acquired brain injury (abi) survivors in nova scotia

Conditions: Caregivers

Summary: the purpose of the present study is to follow unpaid caregivers of abi survivors in nova scotia over time to learn more about their experiences. the study is funded by the government of nova scotia (i.e. department of health and wellness). the present longitudinal cohort study will help increase knowledge about abi caregivers at a provincial level. findings will also be used in developing future interventions to help caregivers in this population. the goals of the research study are: 1. to understand the natural experiences of unpaid caregivers over time. more specifically, the investigators hope to learn about the experiences of unpaid caregivers of acquired brain injury survivors in nova scotia. 2. to examine the connection between study demographic variables (e.g. the amount of time spent caregiving in hours per week), and psychological outcome variables (e.g. caregiver burden). 3. to learn about the relationship between psychological outcome variables (e.g. psychological distress and savouring). 4. to provide a platform for future studies using the trials within cohort (twic) study design.

the investigators are employing a trials within cohorts research design. that is, they are conducting a prospective longitudinal cohort study, with the cohort serving as a platform in which future studies or interventions can be tested. in accordance with this approach, eligible participants who have given consent to be contacted in the future may be selected and approached for future participation in randomized controlled trials.

Eligibility criteria:
inclusion criteria: * participant is an unpaid, informal, caregiver of an abi survivor * participant live in nova scotia * participant is able to read, write and understand english * participant has access to a tablet, smart phone, or computer with high speed internet * participant consents to complete online study questionnaires exclusion criteria: * participant is a paid, professional caregiver of an abi survivor * participant does not live in nova scotia * participant is not able to read, write and understand english * participant does not have access to a tablet, smart phone, or computer with high speed internet * participant does not consent to complete online study questionnaires

Keywords: caregivers acquired brain injury
prognostic factors in patients admitted to an urban teaching hospital with covid-19 infection

Conditions: COVID-19

Summary: as of 27th may 2020, approximately 5.7 million people worldwide are known to have been infected with covid-19 coronavirus and more than 350,000 have died (1). the severity of this viral disease for an individual is associated with a widespread perturbation of immune, physiological and metabolic parameters (2, 3). these whole body changes could be considered characteristic of a systemic inflammatory response to tissue injury and it has been long recognised that a large and ongoing systemic inflammatory response is associated with the development of multiple organ failure and infective disease (4, 5). one of the cardinal signs of severe covid-19 infection is a marked systemic inflammatory response (2). this response bears striking similarity to the systemic inflammatory response experienced by patients undergoing major elective surgical resections for cancer (6, 7). indeed, the systemic inflammatory response and the associated metabolic stress has been most well characterised in major elective surgery, where the relationship between the magnitude of the post-operative systemic inflammatory response and the development of post-operative complications is now well recognised, as is the effect of patient comorbidity on this relationship (8, 9). such work has informed therapeutic manoeuvres including minimally invasive surgery, pre-operative optimisation (e.g. anaesthesia, nutrition and steroids) and enhanced recovery protocols. the aim of the present study was to examine whether routinely collected clinicopathological characteristics of patients with covid-19 on admission were informative on the immune and metabolic stress experienced by patients with covid-19 and whether such characteristics were informative on subsequent outcome.

electronic patient records for patients who attended the emergency department (ed) and acute assessment unit (aau) at glasgow royal infirmary (gri), glasgow, u.k., during the initial 7-week period of the covid-19 pandemic in glasgow city (17th march 2020 - 1st may 2020) were examined for routine clinical, laboratory and clinical outcome data. gri is a university teaching hospital that serves an urban population with a high burden of socio-economic deprivation and offers the full spectrum of adult acute receiving specialties to patients over 16 years old. in line with nhs policy, this study was approved by the nhs greater glasgow and clyde caldicott guardian.

Eligibility criteria:
inclusion criteria: * clinical, radiological and pcr positive covid-19 diagnosis exclusion criteria: * less than 18 years old
the momba mobile application-based community

Conditions: Mental Health Wellness 1

Summary: the investigators' mobile application-based community, termed momba, will provide a bi-directional flow of information on maternal and infant mental health to traditionally underrepresented groups of mothers and their infants. the overall goal of this mobile application-based community of low-income postpartum women and infants is to increase the social support, social networks, and social capital of low-income mothers; thereby, leading to a positive change in the health behaviors, utilization of health services, and mental health status of both mothers and their infants.


Eligibility criteria:
inclusion criteria: * women will be recruited in their third trimester of pregnancy from yale-new haven hospital (ynhh) and followed for 8 months postpartum. * women are eligible if they are over the age of 18, in their third trimester of pregnancy, will deliver a baby at ynhh and receive prenatal care at the women's center. * meet criteria for minor or major depressive disorder. exclusion criteria: * mothers are not eligible to participate if they have previously given birth * are placing the baby for adoption * are planning to move in the next 18 months * are actively suicidal, psychotic or unable to provide informed consent

Keywords: depression stress social support social capital maternal
magnetic resonance imaging-transrectal ultrasound fusion image-guided prostate biopsy following radical prostatectomy in patients with prostate cancer

Conditions: Prostate Cancer

Summary: this pilot clinical trial studies magnetic resonance imaging (mri)-transrectal ultrasound (trus) fusion image-guided prostate biopsy following radical prostatectomy in patients with prostate cancer. diagnostic procedures, such as mri-trus fusion image-guided prostate biopsy may help find and diagnose prostate cancer

primary objectives: i. to evaluate accuracy of the new image-guided targeted needle biopsy using the ex-vivo human prostate as obtained from fresh radical prostatectomy specimens. outline: patients undergo robotic radical prostatectomy, followed by 3 mri-trus fusion image-guided prostate biopsies.

Eligibility criteria:
inclusion criteria: * subjects must have biopsy-proven prostate cancer, or prostate-specific antigen (psa) \>= 4 ng/ml or an abnormal digital rectal examination (dre) if consented before prostate biopsy * subjects must have at least 2, preferably 3, pre-operative magnetic resonance imaging (mri)-identified malignant or benign lesions that measure between 10 mm and 15 mm in diameter within the prostate * subjects must have decided to have their prostate surgically removed exclusion criteria: * patients who do not give informed consent * patients with extracapsular extension of their prostate cancer